Researchers at the Jacobs School of Medicine and Biomedical Sciences have developed a new inhalable form of tuberculosis (TB) treatment that could significantly reduce the burden of current therapy.

In the search for shorter, effective, and safe regimens to treat fluoroquinolone-susceptible, rifampin-resistant tuberculosis (TB), three 9-month regimens incorporating newer and repurposed drugs ...

The researchers found that 80.7% of the patients in the standard-therapy group had favorable outcomes in the modified intention-to-treat analysis. (HealthDay News) — Three all-oral shortened regimens ...

Please provide your email address to receive an email when new articles are posted on . Three all-oral 9-month treatments for drug-resistant tuberculosis were found to be noninferior to standard ...

Tuberculosis remains a public health crisis. The World Health Organization's Global Tuberculosis Report released in November 2024 painted a sobering picture; approximately 8.2 million people were ...

The median time to death was 13 and 24 days in the high-dose and standard-dose groups, respectively, among those who died within 6 months. (HealthDay News) — No benefit of high-dose vs standard-dose ...

March 18, 2003 — Doctors should closely monitor patients treated with rifampin and pyrazinamide for latent tuberculosis, according to a report published in the March 15 issue of the American Journal ...

In a recent study published in the journal Clinical Infectious Diseases, researchers reported on the treatment of rifampin-resistant tuberculosis in the United States (U.S.) using the Food and Drug ...

SEATTLE -- An 8-week tuberculosis (TB) treatment strategy where additional therapy is reserved only for persistent disease or at relapse led to less overall treatment and similar clinical outcomes ...

In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current regimens are needed. We ...

Noninferior efficacy seen for three all-oral regimens compared with standard therapy in intention-to-treat, per-protocol populations. (HealthDay News) — Three all-oral shortened regimens have ...